Perkins Capital Management Inc. Has $1.74 Million Holdings in Exagen Inc. (NASDAQ:XGN)

Perkins Capital Management Inc. cut its position in shares of Exagen Inc. (NASDAQ:XGN) by 7.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 423,721 shares of the company’s stock after selling 35,150 shares during the period. Exagen accounts for about 1.5% of Perkins Capital Management Inc.’s investment portfolio, making the stock its 20th largest position. Perkins Capital Management Inc.’s holdings in Exagen were worth $1,737,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in XGN. Palumbo Wealth Management LLC raised its holdings in Exagen by 13.5% during the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after buying an additional 10,340 shares in the last quarter. Corient Private Wealth LLC acquired a new position in shares of Exagen during the 4th quarter valued at about $45,000. Virtu Financial LLC acquired a new position in shares of Exagen during the 4th quarter valued at about $46,000. Finally, Stonepine Capital Management LLC raised its stake in shares of Exagen by 49.0% in the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after acquiring an additional 175,701 shares in the last quarter. Institutional investors own 75.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on XGN. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price target on shares of Exagen in a report on Monday, January 13th. Canaccord Genuity Group raised their target price on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, William Blair reiterated an “outperform” rating on shares of Exagen in a report on Wednesday, March 12th.

Exagen Stock Performance

XGN opened at $3.88 on Monday. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. The stock’s 50 day moving average price is $3.82 and its two-hundred day moving average price is $3.61. The firm has a market capitalization of $69.44 million, a P/E ratio of -4.13 and a beta of 1.40. Exagen Inc. has a 12-month low of $1.30 and a 12-month high of $6.22.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).